Fusion, established as a spin-out from Queen’s University Belfast, has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology). These technologies and associated microbiological techniques, in addition to supporting Fusion’s own therapeutic and diagnostic R&D, are offered as a service to pharmaceutical, biopharmaceutical and academic researchers, allowing them to achieve their goals faster and more cost effectively. Fusion has expertise in producing specific antibodies for therapeutic, diagnostic and theranostic applications.